Details of the Drug

General Information of Drug (ID: DMQNWRD)

Drug Name
Oxaliplatin
Synonyms Eloxatin (TN); Medac (TN); Oxaliplatin (TN); Oxaliplatin (JAN/USAN/INN)
Indication
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Approved [1], [2]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL
#Ro5 Violations (Lipinski):
0		 Molecular Weight 397.29
Topological Polar Surface Area Not Available
Rotatable Bond Count 0
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 6
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [3]
Clearance
The renal clearance of drug is 10-17 L/h [4]
Half-life
The concentration or amount of drug in body reduced by one-half in 0.43 hours (alpha), and 16.8 hours (beta) [5]
Metabolism
The drug is metabolized via the displacement of the labile oxalate ligand [6]
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 8.1315 micromolar/kg/day [7]
Unbound Fraction
The unbound fraction of drug in plasma is 0.13% [5]
Vd
The volume of distribution (Vd) of drug is 440 L [4]
Water Solubility
The ability of drug to dissolve in water is measured as 6 mg/mL [3]
Chemical Identifiers
Formula
C8H14N2O4Pt
IUPAC Name
[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
Canonical SMILES
C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]
InChI
InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1
InChIKey
DRMCATBEKSVAPL-BNTLRKBRSA-N
Cross-matching ID
PubChem CID
9887053
CAS Number
61825-94-3
DrugBank ID
DB00526
TTD ID
D0Y3ME
VARIDT ID
DR00316
INTEDE ID
DR1210

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Modulator [8]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
High affinity copper uptake protein 1 (SLC31A1) DTP8L4F COPT1_HUMAN Substrate [9]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [10]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [11]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [12]
Organic cation transporter 2 (SLC22A2) DT9IDPW S22A2_HUMAN Substrate [13]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Substrate [14]
Cytochrome P450 1A1 (CYP1A1) DE6OQ3W CP1A1_HUMAN Substrate [14]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Substrate [14]
Cytochrome P450 1B1 (CYP1B1) DE9QHP6 CP1B1_HUMAN Substrate [14]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Substrate [15]
Glutathione S-transferase pi (GSTP1) DEK6079 GSTP1_HUMAN Substrate [15]
Metallothionein-1A (MT1A) DE5ME8A MT1A_HUMAN Substrate [15]
Myeloperoxidase (MPO) DEA3U9Y PERM_HUMAN Substrate [15]
Metallothionein-2A (MT2A) DEFKGT7 MT2_HUMAN Substrate [15]
Glutathione S-transferase mu-1 (GSTM1) DEYZEJA GSTM1_HUMAN Substrate [15]
Superoxide dismutase 1 (SOD1) DEUTDON SODC_HUMAN Substrate [15]
Glutathione S-transferase theta-1 (GSTT1) DE3PKUG GSTT1_HUMAN Substrate [15]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oxaliplatin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Remdesivir DMBFZ6L Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Remdesivir. 1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019] [113]
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Ivosidenib. Acute myeloid leukaemia [2A60] [114]
Midostaurin DMI6E0R Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Midostaurin. Acute myeloid leukaemia [2A60] [115]
Gilteritinib DMWQ4MZ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Gilteritinib. Acute myeloid leukaemia [2A60] [116]
Oliceridine DM6MDCF Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Oliceridine. Acute pain [MG31] [115]
Framycetin DMF8DNE Moderate Decreased renal excretion of Oxaliplatin caused by Framycetin mediated nephrotoxicity. Alcoholic liver disease [DB94] [117]
Galantamine DMEO794 Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Galantamine. Alzheimer disease [8A20] [115]
Rivastigmine DMG629M Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Rivastigmine. Alzheimer disease [8A20] [115]
Donepezil DMIYG7Z Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Donepezil. Alzheimer disease [8A20] [115]
Inotersen DMJ93CT Moderate Decreased renal excretion of Oxaliplatin caused by Inotersen mediated nephrotoxicity. Amyloidosis [5D00] [117]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Ivabradine. Angina pectoris [BA40] [118]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Bepridil. Angina pectoris [BA40] [115]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Dronedarone. Angina pectoris [BA40] [115]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [119]
Hydroxyzine DMF8Y74 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Hydroxyzine. Anxiety disorder [6B00-6B0Z] [115]
Cilostazol DMZMSCT Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Cilostazol. Arterial occlusive disease [BD40] [115]
Voriconazole DMAOL2S Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Voriconazole. Aspergillosis [1F20] [115]
Posaconazole DMUL5EW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Posaconazole. Aspergillosis [1F20] [115]
Levalbuterol DM5YBO1 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Levalbuterol. Asthma [CA23] [120]
Terbutaline DMD4381 Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Terbutaline. Asthma [CA23] [121]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Pirbuterol. Asthma [CA23] [121]
Salbutamol DMN9CWF Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Salbutamol. Asthma [CA23] [120]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Roflumilast. Asthma [CA23] [118]
Formoterol DMSOURV Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Formoterol. Asthma [CA23] [121]
Lisdexamfetamine DM6W8V5 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [118]
Desipramine DMT2FDC Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Desipramine. Attention deficit hyperactivity disorder [6A05] [115]
Ofloxacin DM0VQN3 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ofloxacin. Bacterial infection [1A00-1C4Z] [122]
Kanamycin DM2DMPO Moderate Decreased renal excretion of Oxaliplatin caused by Kanamycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [117]
Ciprofloxacin XR DM2NLS9 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ciprofloxacin XR. Bacterial infection [1A00-1C4Z] [115]
Clarithromycin DM4M1SG Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Clarithromycin. Bacterial infection [1A00-1C4Z] [115]
Sulfamethoxazole DMB08GE Minor Increased risk of prolong QT interval by the combination of Oxaliplatin and Sulfamethoxazole. Bacterial infection [1A00-1C4Z] [115]
Sparfloxacin DMB4HCT Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Sparfloxacin. Bacterial infection [1A00-1C4Z] [122]
Streptomycin DME1LQN Moderate Decreased renal excretion of Oxaliplatin caused by Streptomycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [117]
Gemifloxacin DMHT34O Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Gemifloxacin. Bacterial infection [1A00-1C4Z] [122]
Norfloxacin DMIZ6W2 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Norfloxacin. Bacterial infection [1A00-1C4Z] [122]
Gentamicin DMKINJO Moderate Decreased renal excretion of Oxaliplatin caused by Gentamicin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [117]
Netilmicin DMRD1QK Moderate Decreased renal excretion of Oxaliplatin caused by Netilmicin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [117]
Levofloxacin DMS60RB Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Levofloxacin. Bacterial infection [1A00-1C4Z] [122]
Tobramycin DMUI0CH Moderate Decreased renal excretion of Oxaliplatin caused by Tobramycin mediated nephrotoxicity. Bacterial infection [1A00-1C4Z] [117]
Lomefloxacin DMVRH9C Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lomefloxacin. Bacterial infection [1A00-1C4Z] [115]
Telithromycin DMZ4P3A Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Telithromycin. Bacterial infection [1A00-1C4Z] [115]
Retigabine DMGNYIH Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Retigabine. Behcet disease [4A62] [115]
Etidronic acid DM1XHYJ Moderate Decreased renal excretion of Oxaliplatin caused by Etidronic acid mediated nephrotoxicity. Bone paget disease [FB85] [117]
Pexidartinib DMS2J0Z Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and Pexidartinib. Bone/articular cartilage neoplasm [2F7B] [123]
Eribulin DM1DX4Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Eribulin. Breast cancer [2C60-2C6Y] [115]
Lapatinib DM3BH1Y Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lapatinib. Breast cancer [2C60-2C6Y] [115]
Tamoxifen DMLB0EZ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Tamoxifen. Breast cancer [2C60-2C6Y] [115]
Toremifene DMQYUWG Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Toremifene. Breast cancer [2C60-2C6Y] [115]
Bosutinib DMTI8YE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Bosutinib. Breast cancer [2C60-2C6Y] [118]
PF-04449913 DMSB068 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [124]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [121]
Vilanterol DMF5EK1 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [120]
Salmeterol DMIEU69 Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Salmeterol. Chronic obstructive pulmonary disease [CA22] [121]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [121]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [121]
Phenylbutazone DMAYL0T Moderate Decreased renal excretion of Oxaliplatin caused by Phenylbutazone mediated nephrotoxicity. Chronic pain [MG30] [117]
Ketoprofen DMRKXPT Moderate Decreased renal excretion of Oxaliplatin caused by Ketoprofen mediated nephrotoxicity. Chronic pain [MG30] [117]
Isoproterenol DMK7MEY Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Isoproterenol. Conduction disorder [BC63] [120]
Halothane DM80OZ5 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Halothane. Corneal disease [9A76-9A78] [115]
Propofol DMB4OLE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Propofol. Corneal disease [9A76-9A78] [125]
Sevoflurane DMC9O43 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Sevoflurane. Corneal disease [9A76-9A78] [115]
Methoxyflurane DML0RAE Moderate Decreased renal excretion of Oxaliplatin caused by Methoxyflurane mediated nephrotoxicity. Corneal disease [9A76-9A78] [117]
Probucol DMVZQ2M Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Probucol. Coronary atherosclerosis [BA80] [115]
Clofazimine DMEBOFW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Clofazimine. Crohn disease [DD70] [126]
Mifepristone DMGZQEF Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Mifepristone. Cushing syndrome [5A70] [115]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Pasireotide. Cushing syndrome [5A70] [115]
Osilodrostat DMIJC9X Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Osilodrostat. Cushing syndrome [5A70] [118]
Sertraline DM0FB1J Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Sertraline. Depression [6A70-6A7Z] [115]
Trimipramine DM1SC8M Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trimipramine. Depression [6A70-6A7Z] [115]
Nortriptyline DM4KDYJ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Nortriptyline. Depression [6A70-6A7Z] [115]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Escitalopram. Depression [6A70-6A7Z] [115]
Clomipramine DMINRKW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Clomipramine. Depression [6A70-6A7Z] [115]
Trazodone DMK1GBJ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trazodone. Depression [6A70-6A7Z] [127]
Amoxapine DMKITQE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Amoxapine. Depression [6A70-6A7Z] [115]
Doxepin DMPI98T Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Doxepin. Depression [6A70-6A7Z] [115]
Maprotiline DMPWB7T Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Maprotiline. Depression [6A70-6A7Z] [115]
Tetrabenazine DMYWQ0O Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [115]
Deutetrabenazine DMUPFLI Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Deutetrabenazine. Dystonic disorder [8A02] [128]
Ingrezza DMVPLNC Moderate Additive CNS depression effects by the combination of Oxaliplatin and Ingrezza. Dystonic disorder [8A02] [129]
Cannabidiol DM0659E Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Cannabidiol. Epileptic encephalopathy [8A62] [118]
Mefenamic acid DMK7HFI Moderate Decreased renal excretion of Oxaliplatin caused by Mefenamic acid mediated nephrotoxicity. Female pelvic pain [GA34] [117]
Solifenacin DMG592Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Solifenacin. Functional bladder disorder [GC50] [115]
Pentamidine DMHZJCG Moderate Decreased renal excretion of Oxaliplatin caused by Pentamidine mediated nephrotoxicity. Fungal infection [1F29-1F2F] [117]
Ketoconazole DMPZI3Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ketoconazole. Fungal infection [1F29-1F2F] [115]
Amphotericin B DMTAJQE Moderate Decreased renal excretion of Oxaliplatin caused by Amphotericin B mediated nephrotoxicity. Fungal infection [1F29-1F2F] [117]
Sunitinib DMCBJSR Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [115]
177Lu-DOTATATE DMT8GVU Moderate Decreased renal excretion of Oxaliplatin caused by 177Lu-DOTATATE mediated nephrotoxicity. Hepatitis virus infection [1E50-1E51] [117]
Brentuximab vedotin DMWLC57 Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Brentuximab vedotin. Hodgkin lymphoma [2B30] [130]
Fostemsavir DM50ILT Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [131]
Efavirenz DMC0GSJ Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Efavirenz. Human immunodeficiency virus disease [1C60-1C62] [132]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [133]
Zalcitabine DMH7MUV Moderate Increased risk of peripheral neuropathy by the combination of Oxaliplatin and Zalcitabine. Human immunodeficiency virus disease [1C60-1C62] [134]
Lopinavir DMITQS0 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [115]
Rilpivirine DMJ0QOW Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [115]
Mipomersen DMGSRN1 Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and Mipomersen. Hyper-lipoproteinaemia [5C80] [135]
Teriflunomide DMQ2FKJ Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and Teriflunomide. Hyper-lipoproteinaemia [5C80] [136]
BMS-201038 DMQTAGO Major Increased risk of hepatotoxicity by the combination of Oxaliplatin and BMS-201038. Hyper-lipoproteinaemia [5C80] [137]
Givosiran DM5PFIJ Moderate Decreased renal excretion of Oxaliplatin caused by Givosiran mediated nephrotoxicity. Inborn porphyrin/heme metabolism error [5C58] [117]
Balsalazide DMO091F Moderate Decreased renal excretion of Oxaliplatin caused by Balsalazide mediated nephrotoxicity. Indeterminate colitis [DD72] [117]
Meclofenamic acid DM05FXR Moderate Decreased renal excretion of Oxaliplatin caused by Meclofenamic acid mediated nephrotoxicity. Inflammatory spondyloarthritis [FA92] [117]
Polyethylene glycol DM4I1JP Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Polyethylene glycol. Irritable bowel syndrome [DD91] [118]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Phenolphthalein. Irritable bowel syndrome [DD91] [115]
Methotrexate DM2TEOL Moderate Decreased renal excretion of Oxaliplatin caused by Methotrexate mediated nephrotoxicity. Leukaemia [2A60-2B33] [117]
Ibandronate DM0QZBN Moderate Decreased renal excretion of Oxaliplatin caused by Ibandronate mediated nephrotoxicity. Low bone mass disorder [FB83] [117]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Denosumab. Low bone mass disorder [FB83] [138]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Crizotinib. Lung cancer [2C25] [139]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Ceritinib. Lung cancer [2C25] [115]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Osimertinib. Lung cancer [2C25] [140]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Selpercatinib. Lung cancer [2C25] [118]
Lumefantrine DM29GAD Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Lumefantrine. Malaria [1F40-1F45] [113]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Halofantrine. Malaria [1F40-1F45] [141]
Chloroquine DMSI5CB Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Chloroquine. Malaria [1F40-1F45] [142]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Hydroxychloroquine. Malaria [1F40-1F45] [142]
Primaquine DMWQ16I Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Primaquine. Malaria [1F40-1F45] [115]
Inotuzumab ozogamicin DMAC130 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [118]
Calaspargase pegol DMQZBXI Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Calaspargase pegol. Malignant haematopoietic neoplasm [2B33] [143]
Idelalisib DM602WT Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Idelalisib. Mature B-cell leukaemia [2A82] [144]
Moxetumomab pasudotox DMN63DZ Moderate Decreased renal excretion of Oxaliplatin caused by Moxetumomab pasudotox mediated nephrotoxicity. Mature B-cell leukaemia [2A82] [117]
Clofarabine DMCVJ86 Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Clofarabine. Mature B-cell lymphoma [2A85] [145]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Vemurafenib. Melanoma [2C30] [115]
Exjade DMHPRWG Moderate Decreased renal excretion of Oxaliplatin caused by Exjade mediated nephrotoxicity. Mineral absorption/transport disorder [5C64] [117]
Gallium nitrate DMF9O6B Moderate Decreased renal excretion of Oxaliplatin caused by Gallium nitrate mediated nephrotoxicity. Mineral excesses [5B91] [117]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Panobinostat. Multiple myeloma [2A83] [146]
Thalidomide DM70BU5 Major Additive thrombogenic effects by the combination of Oxaliplatin and Thalidomide. Multiple myeloma [2A83] [147]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Tecfidera. Multiple sclerosis [8A40] [148]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Oxaliplatin and Siponimod. Multiple sclerosis [8A40] [113]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Fingolimod. Multiple sclerosis [8A40] [149]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Ocrelizumab. Multiple sclerosis [8A40] [150]
Ozanimod DMT6AM2 Major Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Ozanimod. Multiple sclerosis [8A40] [118]
Romidepsin DMT5GNL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Romidepsin. Mycosis fungoides [2B01] [115]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Nilotinib. Myeloproliferative neoplasm [2A20] [115]
Dasatinib DMJV2EK Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Dasatinib. Myeloproliferative neoplasm [2A20] [151]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive myelosuppressive effects by the combination of Oxaliplatin and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [152]
Promethazine DM6I5GR Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Promethazine. Nausea/vomiting [MD90] [115]
Granisetron DMIUW25 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Granisetron. Nausea/vomiting [MD90] [115]
Dolasetron DMMG26Z Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Dolasetron. Nausea/vomiting [MD90] [115]
Ondansetron DMOTQ1I Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Ondansetron. Nausea/vomiting [MD90] [115]
Entrectinib DMMPTLH Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Entrectinib. Non-small cell lung cancer [2C25] [113]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Levomethadyl Acetate. Opioid use disorder [6C43] [118]
Lofexidine DM1WXA6 Moderate Additive hypotensive effects by the combination of Oxaliplatin and Lofexidine. Opioid use disorder [6C43] [115]
Rofecoxib DM3P5DA Moderate Decreased renal excretion of Oxaliplatin caused by Rofecoxib mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [117]
Valdecoxib DMAY7H4 Moderate Decreased renal excretion of Oxaliplatin caused by Valdecoxib mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [117]
Diclofenac DMPIHLS Moderate Decreased renal excretion of Oxaliplatin caused by Diclofenac mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [117]
Naproxen DMZ5RGV Moderate Decreased renal excretion of Oxaliplatin caused by Naproxen mediated nephrotoxicity. Osteoarthritis [FA00-FA05] [117]
Rucaparib DM9PVX8 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Rucaparib. Ovarian cancer [2C73] [115]
Dextropropoxyphene DM23HCX Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Dextropropoxyphene. Pain [MG30-MG3Z] [153]
Etodolac DM6WJO9 Moderate Decreased renal excretion of Oxaliplatin caused by Etodolac mediated nephrotoxicity. Pain [MG30-MG3Z] [117]
Diflunisal DM7EN8I Moderate Decreased renal excretion of Oxaliplatin caused by Diflunisal mediated nephrotoxicity. Pain [MG30-MG3Z] [117]
Ibuprofen DM8VCBE Moderate Decreased renal excretion of Oxaliplatin caused by Ibuprofen mediated nephrotoxicity. Pain [MG30-MG3Z] [117]
Buprenorphine DMPRI8G Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Buprenorphine. Pain [MG30-MG3Z] [115]
Piroxicam DMTK234 Moderate Decreased renal excretion of Oxaliplatin caused by Piroxicam mediated nephrotoxicity. Pain [MG30-MG3Z] [117]
Triclabendazole DMPWGBR Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Triclabendazole. Parasitic worm infestation [1F90] [115]
Pimavanserin DMR7IVC Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Pimavanserin. Parkinsonism [8A00] [154]
Apomorphine DMX38HQ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Apomorphine. Parkinsonism [8A00] [115]
Famotidine DMRL3AB Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Famotidine. Peptic ulcer [DA61] [113]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Macimorelin. Pituitary gland disorder [5A60-5A61] [155]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Lefamulin. Pneumonia [CA40] [156]
Bromfenac DMKB79O Moderate Decreased renal excretion of Oxaliplatin caused by Bromfenac mediated nephrotoxicity. Postoperative inflammation [1A00-CA43] [117]
Ritodrine DM4V6RL Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Ritodrine. Preterm labour/delivery [JB00] [121]
Degarelix DM3O8QY Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Degarelix. Prostate cancer [2C82] [118]
ABIRATERONE DM8V75C Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and ABIRATERONE. Prostate cancer [2C82] [118]
Nilutamide DMFN07X Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Nilutamide. Prostate cancer [2C82] [118]
Enzalutamide DMGL19D Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Enzalutamide. Prostate cancer [2C82] [118]
Relugolix DMK7IWL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Relugolix. Prostate cancer [2C82] [118]
Bicalutamide DMZMSPF Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Bicalutamide. Prostate cancer [2C82] [118]
Levomepromazine DMIKFEL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Levomepromazine. Psychotic disorder [6A20-6A25] [115]
Fluphenazine DMIT8LX Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Fluphenazine. Psychotic disorder [6A20-6A25] [115]
Temsirolimus DMS104F Moderate Decreased renal excretion of Oxaliplatin caused by Temsirolimus mediated nephrotoxicity. Renal cell carcinoma [2C90] [117]
Gatifloxacin DMSL679 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Gatifloxacin. Respiratory infection [CA07-CA4Z] [157]
Colistimethate DMZ9BMU Moderate Decreased renal excretion of Oxaliplatin caused by Colistimethate mediated nephrotoxicity. Respiratory infection [CA07-CA4Z] [117]
Salsalate DM13P4C Moderate Decreased renal excretion of Oxaliplatin caused by Salsalate mediated nephrotoxicity. Rheumatoid arthritis [FA20] [117]
Meloxicam DM2AR7L Moderate Decreased renal excretion of Oxaliplatin caused by Meloxicam mediated nephrotoxicity. Rheumatoid arthritis [FA20] [117]
Sulindac DM2QHZU Moderate Decreased renal excretion of Oxaliplatin caused by Sulindac mediated nephrotoxicity. Rheumatoid arthritis [FA20] [117]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Canakinumab. Rheumatoid arthritis [FA20] [158]
Oxaprozin DM9UB0P Moderate Decreased renal excretion of Oxaliplatin caused by Oxaprozin mediated nephrotoxicity. Rheumatoid arthritis [FA20] [117]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Oxaliplatin and Rilonacept. Rheumatoid arthritis [FA20] [158]
Flurbiprofen DMGN4BY Moderate Decreased renal excretion of Oxaliplatin caused by Flurbiprofen mediated nephrotoxicity. Rheumatoid arthritis [FA20] [117]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Oxaliplatin and Golimumab. Rheumatoid arthritis [FA20] [159]
Sulfasalazine DMICA9H Moderate Decreased renal excretion of Oxaliplatin caused by Sulfasalazine mediated nephrotoxicity. Rheumatoid arthritis [FA20] [117]
Fenoprofen DML5VQ0 Moderate Decreased renal excretion of Oxaliplatin caused by Fenoprofen mediated nephrotoxicity. Rheumatoid arthritis [FA20] [117]
Leflunomide DMR8ONJ Major Additive immunosuppressive effects by the combination of Oxaliplatin and Leflunomide. Rheumatoid arthritis [FA20] [136]
Quetiapine DM1N62C Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Quetiapine. Schizophrenia [6A20] [115]
Mesoridazine DM2ZGAN Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Mesoridazine. Schizophrenia [6A20] [115]
Thioridazine DM35M8J Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Thioridazine. Schizophrenia [6A20] [115]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Aripiprazole. Schizophrenia [6A20] [113]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Iloperidone. Schizophrenia [6A20] [115]
Paliperidone DM7NPJS Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Paliperidone. Schizophrenia [6A20] [115]
Perphenazine DMA4MRX Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Perphenazine. Schizophrenia [6A20] [115]
Trifluoperazine DMKBYWI Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trifluoperazine. Schizophrenia [6A20] [115]
Risperidone DMN6DXL Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Risperidone. Schizophrenia [6A20] [115]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Amisulpride. Schizophrenia [6A20] [160]
Asenapine DMSQZE2 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Asenapine. Schizophrenia [6A20] [115]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Pimozide. Schizophrenia [6A20] [118]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Oxaliplatin when combined with Anthrax vaccine. Sepsis [1G40-1G41] [161]
Vardenafil DMTBGW8 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Vardenafil. Sexual dysfunction [HA00-HA01] [115]
Bacitracin DM5OHYE Moderate Decreased renal excretion of Oxaliplatin caused by Bacitracin mediated nephrotoxicity. Skin and skin-structure infection [1F28-1G0Z] [117]
Trabectedin DMG3Y89 Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Trabectedin. Solid tumour/cancer [2A00-2F9Z] [118]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Oxaliplatin and LEE011. Solid tumour/cancer [2A00-2F9Z] [115]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [115]
Triptorelin DMTK4LS Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [118]
Pitolisant DM8RFNJ Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Pitolisant. Somnolence [MG42] [115]
Telavancin DM58VQX Moderate Decreased renal excretion of Oxaliplatin caused by Telavancin mediated nephrotoxicity. Staphylococcal/streptococcal disease [1B5Y] [117]
Naltrexone DMUL45H Moderate Increased risk of hepatotoxicity by the combination of Oxaliplatin and Naltrexone. Substance abuse [6C40] [162]
Adenosine DMM2NSK Moderate Increased risk of ventricular arrhythmias by the combination of Oxaliplatin and Adenosine. Supraventricular tachyarrhythmia [BC81] [115]
Lenvatinib DMB1IU4 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Lenvatinib. Thyroid cancer [2D10] [115]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Cabozantinib. Thyroid cancer [2D10] [118]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Papaverine. Tonus and reflex abnormality [MB47] [163]
Tizanidine DMR2IQ4 Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Tizanidine. Tonus and reflex abnormality [MB47] [115]
Sirolimus DMGW1ID Moderate Decreased renal excretion of Oxaliplatin caused by Sirolimus mediated nephrotoxicity. Transplant rejection [NE84] [117]
Azathioprine DMMZSXQ Moderate Additive myelosuppressive effects by the combination of Oxaliplatin and Azathioprine. Transplant rejection [NE84] [113]
Tacrolimus DMZ7XNQ Moderate Decreased renal excretion of Oxaliplatin caused by Tacrolimus mediated nephrotoxicity. Transplant rejection [NE84] [117]
Olsalazine DMZW9HA Moderate Decreased renal excretion of Oxaliplatin caused by Olsalazine mediated nephrotoxicity. Ulcerative colitis [DD71] [117]
Astemizole DM2HN6Q Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Astemizole. Vasomotor/allergic rhinitis [CA08] [115]
Trimeprazine DMEMV9D Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [153]
Procainamide DMNMXR8 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Procainamide. Ventricular tachyarrhythmia [BC71] [115]
Propafenone DMPIBJK Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Propafenone. Ventricular tachyarrhythmia [BC71] [115]
Flecainide DMSQDLE Moderate Increased risk of prolong QT interval by the combination of Oxaliplatin and Flecainide. Ventricular tachyarrhythmia [BC71] [115]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Oxaliplatin and Amiodarone. Ventricular tachyarrhythmia [BC71] [115]
Ganciclovir DM1MBYQ Moderate Increased risk of nephrotoxicity by the combination of Oxaliplatin and Ganciclovir. Virus infection [1A24-1D9Z] [113]
Valaciclovir DMHKS94 Moderate Increased risk of nephrotoxicity by the combination of Oxaliplatin and Valaciclovir. Virus infection [1A24-1D9Z] [118]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Oxaliplatin and Valganciclovir. Virus infection [1A24-1D9Z] [113]
⏷ Show the Full List of 221 DDI Information of This Drug

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7433).
2 The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer. Gan To Kagaku Ryoho. 2009 May;36(5):797-801.
3 BDDCS applied to over 900 drugs
4 An FDA phase I clinical trial of quinacrine sterilization (QS). Int J Gynaecol Obstet. 2003 Oct;83 Suppl 2:S45-9.
5 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
6 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
7 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8 Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
9 Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol. 2005 Jan;53(1):13-23.
10 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
11 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
12 Effect of ABCG2 on cytotoxicity of platinum drugs: interference of EGFP. Toxicol In Vitro. 2008 Dec;22(8):1846-52.
13 Relevance of copper transporter 1 and organic cation transporters 1-3 for oxaliplatin uptake and drug resistance in colorectal cancer cells. Metallomics. 2018 Mar 1;10(3):414-425.
14 The influence of metabolic gene polymorphisms on urinary 1-hydroxypyrene concentrations in Chinese coke oven workers. Sci Total Environ. 2007 Aug 1;381(1-3):38-46.
15 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
16 Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes. Drug Metab Dispos. 2000 Dec;28(12):1457-63.
17 Effects of polyunsaturated fatty acids on prostaglandin synthesis and cyclooxygenase-mediated DNA adduct formation by heterocyclic aromatic amines in human adenocarcinoma colon cells. Mol Carcinog. 2004 Jul;40(3):180-8.
18 Endoxifen and other metabolites of tamoxifen inhibit human hydroxysteroid sulfotransferase 2A1 (hSULT2A1). Drug Metab Dispos. 2014 Nov;42(11):1843-50.
19 Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study. Breast Cancer Res. 2004;6(4):R352-65.
20 PharmGKB summary: pathways of acetaminophen metabolism at the therapeutic versus toxic doses. Pharmacogenet Genomics. 2015 Aug;25(8):416-26.
21 The effect of apigenin on pharmacokinetics of imatinib and its metabolite N-desmethyl imatinib in rats. Biomed Res Int. 2013;2013:789184.
22 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
23 Identification of P450 enzymes involved in metabolism of verapamil in humans. Naunyn Schmiedebergs Arch Pharmacol. 1993 Sep;348(3):332-7.
24 Metabolism and metabolic inhibition of xanthotoxol in human liver microsomes. Evid Based Complement Alternat Med. 2016;2016:5416509.
25 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
26 Allelic variants of human cytochrome P450 1A1 (CYP1A1): effect of T461N and I462V substitutions on steroid hydroxylase specificity. Pharmacogenetics. 2000 Aug;10(6):519-30.
27 Metabolism of tamoxifen by recombinant human cytochrome P450 enzymes: formation of the 4-hydroxy, 4'-hydroxy and N-desmethyl metabolites and isomerization of trans-4-hydroxytamoxifen. Drug Metab Dispos. 2002 Aug;30(8):869-74.
28 Cytochrome P450 isoforms catalyze formation of catechol estrogen quinones that react with DNA. Metabolism. 2007 Jul;56(7):887-94.
29 Preferred orientations in the binding of 4'-hydroxyacetanilide (acetaminophen) to cytochrome P450 1A1 and 2B1 isoforms as determined by 13C- and 15N-NMR relaxation studies. J Med Chem. 1994 Mar 18;37(6):860-7.
30 Diclofenac and its derivatives as tools for studying human cytochromes P450 active sites: particular efficiency and regioselectivity of P450 2Cs. Biochemistry. 1999 Oct 26;38(43):14264-70.
31 A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin Chem Lab Med. 2005;43(7):702-6.
32 Cytochromes P450 in crustacea. Comp Biochem Physiol C Pharmacol Toxicol Endocrinol. 1998 Nov;121(1-3):157-72.
33 Disruption of endogenous regulator homeostasis underlies the mechanism of rat CYP1A1 mRNA induction by metyrapone. Biochem J. 1998 Apr 1;331 ( Pt 1):273-81.
34 Pharmacogenomics in drug-metabolizing enzymes catalyzing anticancer drugs for personalized cancer chemotherapy. Curr Drug Metab. 2007 Aug;8(6):554-62.
35 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
36 Chronic ethanol feeding and folate deficiency activate hepatic endoplasmic reticulum stress pathway in micropigs. Am J Physiol Gastrointest Liver Physiol. 2005 Jul;289(1):G54-63.
37 Cytochrome P450 2E1 null mice provide novel protection against cisplatin-induced nephrotoxicity and apoptosis. Kidney Int. 2003 May;63(5):1687-96.
38 Genotoxicity of tamoxifen, tamoxifen epoxide and toremifene in human lymphoblastoid cells containing human cytochrome P450s. Carcinogenesis. 1994 Jan;15(1):5-9.
39 Acetaminophen induced acute liver failure via oxidative stress and JNK activation: protective role of taurine by the suppression of cytochrome P450 2E1. Free Radic Res. 2010 Mar;44(3):340-55.
40 A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998 Sep;286(3):1294-300.
41 Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
42 Novel metabolic pathway of estrone and 17beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000 Feb;28(2):110-2.
43 Inhibition of cytochrome P450 2E1 by propofol in human and porcine liver microsomes. Biochem Pharmacol. 2002 Oct 1;64(7):1151-6.
44 CYP2E1 and clinical features in alcoholics. Neuropsychobiology. 2003;47(2):86-9.
45 Effects of nicotine on cytochrome P450 2A6 and 2E1 activities. Br J Clin Pharmacol. 2010 Feb;69(2):152-9.
46 Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis. 1999 Aug;20(8):1607-13.
47 Pharmacokinetics of rosuvastatin when coadministered with rifampicin in healthy males: a randomized, single-blind, placebo-controlled, crossover study. Clin Ther. 2008 Jul;30(7):1283-9.
48 Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004 Aug;32(8):840-7.
49 Oxidation of xenobiotics by recombinant human cytochrome P450 1B1. Drug Metab Dispos. 1997 May;25(5):617-22.
50 Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005 Apr;33(4):489-94.
51 Human CYP1B1 and anticancer agent metabolism: mechanism for tumor-specific drug inactivation? J Pharmacol Exp Ther. 2001 Feb;296(2):537-41.
52 Glutathione S-transferase genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin. Anticancer Drugs. 2000 Sep;11(8):639-43.
53 Reactions of glutathione with the catechol, the ortho-quinone and the semi-quinone free radical of etoposide. Consequences for DNA inactivation. Biochem Pharmacol. 1992 Apr 15;43(8):1761-8.
54 Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos. 1996 Sep;24(9):1015-9.
55 The anti-cancer drug chlorambucil as a substrate for the human polymorphic enzyme glutathione transferase P1-1: kinetic properties and crystallographic characterisation of allelic variants. J Mol Biol. 2008 Jun 27;380(1):131-44.
56 Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer. 2000 Mar 15;85(6):777-81.
57 Cisplatin reduces Brucella melitensis-infected cell number by inducing apoptosis, oxidant and pro-inflammatory cytokine production. Res Vet Sci. 2010 Apr;88(2):218-26.
58 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
59 Thiols as peroxidase substrates. Free Radic Biol Med. 1993 Feb;14(2):167-75.
60 Proteomic profile of aminoglutethimide-induced apoptosis in HL-60 cells: role of myeloperoxidase and arylamine free radicals. Chem Biol Interact. 2015 Sep 5;239:129-38.
61 Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
62 Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
63 Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
64 Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.
65 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
66 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
67 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
68 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
69 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
70 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
71 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
72 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
73 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
74 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
75 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
76 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
77 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
78 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
79 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
80 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
81 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
82 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
83 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
84 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
85 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
86 Cisplatin nephrotoxicity is critically mediated via the human organic cation transporter 2. Am J Pathol. 2005 Dec;167(6):1477-84.
87 Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 1997 Jul;16(7):871-81.
88 Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52.
89 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
90 The organic cation transporters (OCT1, OCT2, EMT) and the plasma membrane monoamine transporter (PMAT) show differential distribution and cyclic expression pattern in human endometrium and early pregnancy decidua. Mol Reprod Dev. 2007 Oct;74(10):1303-11.
91 Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab Pharmacokinet. 2005 Oct;20(5):379-86.
92 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
93 Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2. Drug Metab Pharmacokinet. 2010;25(4):328-34.
94 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
95 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
96 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
97 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
98 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
99 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
100 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
101 Overcoming platinum drug resistance with copper-lowering agents. Anticancer Res. 2013 Oct;33(10):4157-61.
102 Role of the copper transporter, CTR1, in platinum-induced ototoxicity. J Neurosci. 2010 Jul 14;30(28):9500-9.
103 Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
104 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
105 Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
106 O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
107 Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
108 DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
109 Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
110 Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
111 Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.
112 Alkylation of DNA by melphalan in relation to immunoassay of melphalan-DNA adducts: characterization of mono-alkylated and cross-linked products fr... Chem Biol Interact. 1990;73(2-3):183-94.
113 Cerner Multum, Inc. "Australian Product Information.".
114 Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
115 Canadian Pharmacists Association.
116 Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
117 Product Information. Eloxatin (oxaliplatin). Sanofi Winthrop Pharmaceuticals, New York, NY.
118 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
119 Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
120 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
121 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
122 Ball P "Quinolone-induced QT interval prolongation: a not-so-unexpected class effect." J Antimicrob Chemother 45 (2000): 557-9. [PMID: 10797074]
123 Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
124 Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
125 Hanci V, Aydin M, Yurtlu BS, et.al "Anesthesia induction with sevoflurane and propofol: evaluation of P-wave dispersion, QT and corrected QT intervals." Kaohsiung J Med Sci 26 (2010): 470-7. [PMID: 20837343]
126 Product Information. Lamprene (clofazimine). Novartis Pharmaceuticals, East Hanover, NJ.
127 Antonelli D, Atar S, Freedberg NA, Rosenfeld T "Torsade de pointes in patients on chronic amiodarone treatment: contributing factors and drug interactions." Isr Med Assoc J 7 (2005): 163-5. [PMID: 15792261]
128 Product Information. Austedo (deutetrabenazine). Teva Pharmaceuticals USA, North Wales, PA.
129 Product Information. Ingrezza (valbenazine). Neurocrine Biosciences, Inc., San Diego, CA.
130 Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
131 Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
132 Product Information. Sustiva (efavirenz). DuPont Pharmaceuticals, Wilmington, DE.
133 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
134 Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
135 Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
136 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
137 Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
138 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
139 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
140 Product Information. Tagrisso (osimertinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
141 Abernethy DR, Wesche DL, Barbey JT, et al. "Stereoselective halofantrine disposition and effect: concentration-related QTc prolongation." Br J Clin Pharmacol 51 (2001): 231-7. [PMID: 11298069]
142 Harper KM, Knapp DJ, Criswell HE, Breese GR "Vasopressin and alcohol: A multifaceted relationship." Psychopharmacology (Berl) 235 (2018): 3363-79. [PMID: 32936259]
143 Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
144 Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
145 Product Information. Clolar (clofarabine). sanofi-aventis, Bridgewater, NJ.
146 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
147 Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
148 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
149 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
150 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
151 Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
152 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
153 Iannini PB "Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval." Expert Opin Drug Saf 1 (2002): 121-8. [PMID: 12904146]
154 Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
155 Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
156 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
157 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
158 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
159 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
160 Product Information. Barhemsys (amisulpride). Acacia Pharma, Inc, Indianapolis, IN.
161 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
162 Product Information. ReVia (naltrexone). DuPont Pharmaceuticals, Wilmington, DE.
163 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]